Screener
Recursion Pharmaceuticals, Inc. RXRX Assets, Fair Value Disclosure
Assets, Fair Value Disclosure at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsFairValueDisclosure.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| (in thousands) | June 30, 2026 | Basis of fair value measurement / Level 1 | Basis of fair value measurement / Level 2 | Basis of fair value measurement / Level 3 |
|---|---|---|---|---|
| Assets | ||||
| Cash and cash equivalents: | ||||
| Cash | $9,545 | $9,545 | — | — |
| Money market funds | 536,138 | 536,138 | — | — |
| Restricted cash | 11,137 | 11,137 | — | — |
| Total | $556,820 | $556,820 | — | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s assets, fair value disclosure?
- Recursion Pharmaceuticals, Inc. (RXRX) reported assets, fair value disclosure of $556.82M in Q2 2026.
- What does assets, fair value disclosure mean?
- Assets, Fair Value Disclosure as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s assets, fair value disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude